R 94138

11/01/2000 - "In this study, we investigated the effect of R-94138 on the invasive and lymphnodal metastatic ability of gastric cancer cells. "
01/01/1999 - "R-94138 seems to be a promising candidate to prevent peritoneal dissemination of gastric cancer."
01/01/1999 - "R-94138, a matrix metalloproteinase inhibitor, was examined for the ability to prevent peritoneal dissemination of a human gastric cancer xenograft, TMK-1. "
06/01/2001 - "In this study, we investigated the effect of R-94138, a matrix metalloproteinase (MMP) inhibitor, on the lymphnodal metastatic ability of gastric cancer cells using an in vivo orthotopic implantation model in nude mice. "
01/01/1999 - "Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice."

06/01/2001 - "The number of lymph node metastases and the amount of body weight loss significantly decreased by intraperitoneal administration of R-94138. "
11/01/2000 - "The number of lymph node metastases and the amount of body weight loss were significantly decreased by intraperitoneal administration of R-94138. "
11/01/2000 - "Inhibition of invasion and lymph node metastasis of gastrointestinal cancer cells by R-94138, a matrix metalloproteinase inhibitor."
06/01/2001 - "These findings suggested that the MMP inhibitor, R-94138, could be used in adjunctive therapy for lymph node metastasis in gastric carcinoma."
11/01/2000 - "MMP inhibitor, R-94138, has a possible application in adjunctive therapy for lymph node metastasis in gastric carcinoma."

06/01/2001 - "These findings suggested that the MMP inhibitor, R-94138, could be used in adjunctive therapy for lymph node metastasis in gastric carcinoma."
11/01/2000 - "MMP inhibitor, R-94138, has a possible application in adjunctive therapy for lymph node metastasis in gastric carcinoma."

06/01/2001 - "The number of lymph node metastases and the amount of body weight loss significantly decreased by intraperitoneal administration of R-94138. "
11/01/2000 - "The number of lymph node metastases and the amount of body weight loss were significantly decreased by intraperitoneal administration of R-94138. "

01/01/1999 - "When the maximum tolerated dose of mitomycin C (MMC) or cisplatin (DDP) was given 12 h after the tumor inoculation, peritoneal dissemination was completely inhibited, while the effect of R-94138 was limited when it was given i.p. "